<DOC>
	<DOCNO>NCT03044353</DOCNO>
	<brief_summary>The study intend evaluate whether monthly repeat course administration GSK2315698 follow GSK2398852 associate reduction cardiac amyloid load patient cardiac amyloidosis , monitor cardiac magnetic resonance imaging ( CMR ) echocardiography ( ECHO ) , whether associate improvement cardiac function . Cohort 1 transthyretin cardiomyopathy ( ATTR-CM ) , cohort 2 patient immunoglobulin light chain ( AL ) systemic amyloidosis great 6 month post chemotherapy , cohort 3 newly diagnose AL systemic amyloidosis undergo chemotherapy . Primary objective study assessment reduction cardiac amyloid load repeat administration Anti-SAP treatment evaluate CMR study group assessment safety &amp; tolerability repeat administration Anti-SAP treatment , include compatibility chemotherapy treatment patient AL systemic amyloidosis . This open label , non-randomised , three-group , monthly repeat Anti-SAP treatment study systemic amyloidosis patient cardiac dysfunction cause cardiac amyloidosis . Subjects receive 6 course Anti-SAP treatment . Maximum total duration subject study approximately 18 month .</brief_summary>
	<brief_title>Multiple Treatment Session Study Assess GSK2398852 Administered Following Along With GSK2315698</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Between 18 80 year age inclusive , time signing informed consent . Male female . Males : Male subject female partner child bear potential must comply follow contraception requirement time first dose study medication cycle spermatogenesis follow five terminal halflives last dose study medication . Vasectomy documentation azoospermia . Male condom plus partner use one contraceptive option : Contraceptive subdermal implant , Intrauterine device intrauterine system , Combined Oral Contraceptive Injectable progestogen , Contraceptive vaginal ring , Percutaneous contraceptive patch . This allinclusive list method meet follow GlaxoSmithKline ( GSK ) definition highly effective : failure rate le 1 % per year use consistently correctly , applicable , accordance product label . For nonproduct method ( e.g. , male sterility ) , investigator determines consistent correct use . The GSK definition base definition provide International Conference Harmonisation Technical Requirements Registration Pharmaceuticals Human Use ( ICH ) . The investigator responsible ensure subject understand properly use method contraception . Females A female subject eligible participate pregnant ( confirm negative Urine human chorionic gonadotrophin [ hCG ] test ) , lactate , least one follow condition applies : • Nonreproductive potential define : Premenopausal females one following : Documented tubal ligation ; Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion ; Hysterectomy ; Documented Bilateral Oophorectomy . Postmenopausal define : 60 year old ; Twelve ( 12 ) month spontaneous amenorrhea appropriate clinical profile , e.g . age appropriate , &gt; 45 year , absence hormone replacement therapy ( HRT ) medical suppression menstrual cycle ( e.g . leuprolide treatment ) questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) oestradiol level consistent menopause ( refer laboratory reference range confirmatory level ) . Females HRT whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . • Reproductive potential agrees follow one option list Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) ( As mention study protocol ) 30 day prior first dose study medication 3 month last dose study medication . The investigator responsible ensure subject understand properly use method contraception Capable give write informed consent , include compliance requirement restriction list consent form LateGadolinum enhancement ( LGE ) CMR indicative cardiac amyloidosis LV mass CMR &gt; 200 gram ( g ) Inclusion Criteria Group 1 Transthyretin amyloid ( ATTR ) cardiomyopathy ( CM ) Subjects diagnosis hereditary ATTR amyloidosis know amyloidogenic transthyretin ( TTR ) mutation demonstrate genotyping AND recognise primarily associate cardiomyopathy AND one following : Definite histochemical identification amyloid Congo red stain green birefringence cross polarised light cardiac tissue biopsy identification TTR amyloid fibril protein either immunohistochemistry proteomic analysis . Or Scintigraphy : 99m^TcDPD Grade 2 cardiac uptake 99m^TcPYP either Grade 2 3 cardiac uptake . Subjects diagnosis wild type ATTRCM must negative genotyping one following : Definite histochemical identification amyloid Congo red stain green birefringence cross polarised light cardiac tissue biopsy identification TTR amyloid fibril protein either immunohistochemistry proteomic analysis OR Scintigraphy 99m^Technetiumdicarboxypropane diphosphonate ( 99m^TcDPD ) Grade 2 cardiac uptake 99m^ Technetiumpyrophosphate ( 99m^TcPYP ) Grade 2 3 cardiac uptake . Clinically stable New York heart association ( NYHA ) class 2 3 3 month precede screen Inclusion Criteria Group 2 Subject medically diagnose AL amyloidosis require chemotherapy autologous stem cell transplant base upon : AL amyloidosis confirm biopsy immunohistochemical stain proteomic identification AL amyloid fibril type , subject definite monoclonal gammopathy causative mutation know relevant amyloidogenic gene exclude Clinically stable NYHA class 2 3 3 month precede screen &gt; =6 month complete line chemotherapy , autologous stem cell transplantation , attain either good partial response ( VGPR ) complete response ( CR ) , without need haematological maintenance therapy Inclusion Criteria Group 3 Newly diagnose AL amyloidosis base upon : AL amyloidosis confirm biopsy immunohistochemical stain proteomic identification AL amyloid fibril type subject definite monoclonal gammopathy causative mutation know relevant amyloidogenic gene exclude Mayo stage II IIIa Confirmed free light chain complete response ( CR ) first three cycle firstline chemotherapy least first cycle cyclophosphamide , bortezomib , dexamethasone ( CyBorD ) . Cardiomyopathy primarily cause nonamyloid disease ( e.g . ischemic heart disease ; valvular heart disease ) Interval Q wave ECG point T use Fredericia 's formula ( QTcF ) &gt; 500 millisecond ( msec ) Sustained / symptomatic monomorphic ventricular tachycardia ( VT ) , rapid polymorphic VT , screen Unstable heart failure define emergency hospitalization worsening , decompensated heart failure , syncopal episode within 1 month screening . Implantable cardiac defibrillator ( ICD ) permanent pacemaker ( PPM ) screen Nterminal pro btype Natriuretic Peptide [ ( NT ) proBNP ] &gt; 8500 nanogram ( ng ) / Liter ( L ) Glomerular filtration rate ( GFR ) Screening &lt; 40 milliliter ( mL ) /minute ( min ) Any active persistent dermatological condition Existing diagnosis type dementia History allogeneic stem cell transplantation , prior solid organ transplant , anticipate undergo solid organ transplantation , leave ventricular assist device ( LVAD ) implantation , course study . Malignancy within last 5 year , except basal squamous cell carcinoma skin , carcinoma situ cervix successfully treat . Acute coronary syndrome , form coronary revascularization procedure ( include coronary artery bypass graft [ CABG ] ) , within 6 month screen . Stroke within 6 month screen , transient ischaemic attack ( TIA ) within 3 month screen Symptomatic , clinically significant autonomic neuropathy Principal Investigator ( PI ) feel preclude administration study treatment Hypoalbuminaemia ( serum albumin &lt; 30 g/L ) Uncontrolled hypertension screen Alanine transaminase ALT &gt; 3x upper limit normal ( ULN ) AND bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Peripheral oedema Screening opinion Prinicpal Investigator ( PI ) designee might prevent adequate absorption subcutaneously administer CPHPC Urine dipstick positive ( &gt; 1+ ) blood screen investigation indicate glomerular haematuria . If cause identify , subject may enrol resolution abnormality Presence comorbid uncontrolled medical condition ( e.g . diabetes mellitus ) , opinion investigator would increase potential risk subject . Investigator liaise Medical Monitor uncertainty eligibility patient Positive test hepatitis B hepatitis C , / human immunodeficiency virus ( HIV ) screening , within 3 month prior first dose study treatment Unwillingness inability follow procedure outline protocol Use GSK2315698 ( CPHPC ) , participation separate clinical trial involve CPHPC within 3 month screen Any prohibit concomitant medication per protocol within 28 day Screening Donation blood blood product excess 500 mL within 84 day screen Lactating female Poor unsuitable venous access Treatment another investigational drug , biological agent , device within 6 month screen , 5 halflives study agent , whichever longer . History sensitivity study medication , metabolite thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation CARDIAC MAGNETIC RESONANCE ( CMR ) SCANNING Orthopnoea sufficient severity preclude supine scanning determine screen Contraindication magnetic resonance imaging ( MRI ) contrast agent Inability fit inside scanner due body size ( girth ) Contraindication MRI scanning ( assessed local MRI safety questionnaire ) , include limited : Intracranial aneurysm clip ( except Sugita ) metallic object Intra orbital metal fragment remove Pacemakers implanted cardiac rhythm management/monitoring device nonMR conditional heart valves Inner ear implant History claustrophobia 99m^TCPYP OR 99mTCDPD BONE TRACER RADIOSCINTOGRAPHY Orthopnoea sufficient severity preclude supine scanning determine Screening Previous allergic reaction radioisotope bone tracer Previous inclusion research protocol involve nuclear medicine , positron emission tomography ( PET ) radiological investigation significant radiation burden ( significant radiation burden define 10 mSv addition natural background radiation , previous 3 year ) . Exclusion Criteria Group 1 Has following : Fulfilment diagnostic criterion AL amyloidosis TTR polyneuropathy / intracranial TTR involvement include ophthalmological disease Nonamyloidosis relate chronic liver disease ( exception Gilbert 's syndrome clinically asymptomatic gallstone ) Platelet count &lt; 125x10^9 / L Exclusion criterion Group 2 Chronic liver disease current active liver biliary disease attributable amyloidosis ( exception Gilbert 's syndrome asymptomatic gallstone ) . Exclusion criterion Group 3 Chronic liver disease current active liver biliary disease attributable amyloidosis ( exception Gilbert 's syndrome asymptomatic gallstone ) . Platelet count &lt; 75x10^9 /L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>echocardiography ( ECHO )</keyword>
	<keyword>skin biopsy</keyword>
	<keyword>monoclonal anti-serum amyloid p component antibody ( anti-SAP mAb )</keyword>
	<keyword>Amyloidosis</keyword>
	<keyword>cardiac magnetic resonance imaging ( CMR )</keyword>
	<keyword>biomarkers</keyword>
	<keyword>cardiac functional measure</keyword>
	<keyword>leave ventricular mass</keyword>
</DOC>